Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSY244 in Atrial Fibrillation
NCT04582409Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of HSY244 in Atrial fibrillation (AFib), sponsored by Novartis. Started Nov 2020; status: terminated.
02
Drugs
HSY244
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04582409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04582409.